| Identification | More | [Name]
VITAMIN D3 | [CAS]
511-28-4 | [Synonyms]
5,7,10(19)-CHOLESTATRIEN-3BETA-OL-9,10-SECO
7-DEHYDROCHOLESTEROL
7-DEHYDROCHOLESTEROL ACTIVATED
9,10-SECOCHOLESTA-5,7,10(19)-TRIEN-3BETA-OL
9,10-SECOCHOLESTA-5,7,19(19)-TRIEN-3-OL-(3B,5Z,7E)-CHOLECIFEROL
ACTIVATED 7-DEHYDROCHOLESTEROL
ANTI-RACHITIC VITAMIN
CALCIOL
CHOLECALCIFEROL
CHOLECALCIFEROLUM
COLECALCIFEROL
OLEOVITAMIN D3
RACUMIN D
VITAMIN D
(+)-VITAMIN D3
VITAMIN D3
9,10-secoergosta-5(Z),7(E),10(19)-trien-3beta-ol
Duphafral
VITAMINE D4
CHOLECALCIFEROL (VITAMIN D3) USP(CRM STANDARD) | [EINECS(EC#)]
200-673-2 | [Molecular Formula]
C27H44O | [MDL Number]
MFCD00078131 | [Molecular Weight]
384.64 | [MOL File]
511-28-4.mol |
| Chemical Properties | Back Directory | [Melting point ]
83-86 °C(lit.) | [alpha ]
D18 +89.3° (c = 0.47 in acetone) | [Boiling point ]
504.9±29.0 °C(Predicted) | [density ]
0.96 | [storage temp. ]
2-8°C
| [solubility ]
Soluble in Chloroform | [form ]
Powder | [pka]
14.74±0.20(Predicted) | [color ]
Off-white to light yellow | [Stability:]
Hygroscopic, Temperature Sensitive | [InChIKey]
DIPPFEXMRDPFBK-JPWDPSJFSA-N | [SMILES]
[C@H]1(O)CCC(=C)/C(=C\C=C2/CCC[C@@]3(C)[C@@]/2([H])CC[C@@H]3[C@H](C)CC[C@H](C)C(C)C)/C1 | [CAS DataBase Reference]
511-28-4(CAS DataBase Reference) |
| Safety Data | Back Directory | [Hazard Codes ]
T+ | [Risk Statements ]
R24/25:Toxic in contact with skin and if swallowed .
R26:Very Toxic by inhalation.
R48/25:Toxic: danger of serious damage to health by prolonged exposure if swallowed . | [Safety Statements ]
S28:After contact with skin, wash immediately with plenty of ... (to be specified by the manufacturer) .
S36/37:Wear suitable protective clothing and gloves . | [RIDADR ]
UN 2811 6.1/PG 2
| [WGK Germany ]
2
| [RTECS ]
VS2900000
| [F ]
8-10-23 | [Storage Class]
6.1A - Combustible acute toxic Cat. 1 and 2
very toxic hazardous materials | [Hazard Classifications]
Acute Tox. 2 Inhalation
Acute Tox. 3 Dermal
Acute Tox. 3 Oral
STOT RE 1 Oral |
| Hazard Information | Back Directory | [Description]
Derived from cholesterol, vitamin D is biosynthesized from its prohormone cholecalciferol (D3), the product of
solar ultraviolet irradiation of 7-dehydrocholesterol in the skin.
In 1966, it was first recognized that vitamin
D must undergo activation via two oxidative metabolic steps. The first oxidation to
25-hydroxycholecalciferol (25(OH)D3: calcifediol; Calderol) occurs in the endoplasmic reticulum of the liver and
is catalyzed by vitamin D 25-hydroxylase. This activation step is not
regulated by plasma calcium concentrations. The major circulating form (10–80 μg/mL) is 25(OH)D3, which also
is the primary storage form of vitamin D. | [Chemical Properties]
Pale Yellow Oil | [Uses]
Vitamin D4 is the active analogue of Vitamin D. | [Definition]
ChEBI: Vitamin D4 is it is present in mushrooms. It has a role as a fungal metabolite. It is a vitamin D and a seco-ergostane. | [Biological Functions]
Sterol-specific cytoplasmic receptor proteins (vitamin D receptor) mediate the biological action of vitamin D.
The active hormone is transported from the cytoplasm to the nucleus via the vitamin D receptor, and as a result
of the interaction of the hormone with target genes, a variety of proteins are produced that stimulate the
transport of calcium in each of the target tissues
Active vitamin D works in concert with PTH to enhance active
intestinal absorption of calcium, to stimulate bone resorption, and to prohibit renal excretion of calcium. If
serum calcium or 1,25-calcitriol concentrations are elevated, then vitamin D 24-hydroxylase (in renal
mitochondria) is activated to oxidize 25(OH)D3 to inactive 24,25-dihydroxy-cholecalciferol and to further oxidize
active vitamin D to the inactive 1,24,25-trihydroxylated derivative. Both the 1,24,25-trihydroxylated and the
24,25-dihydroxylated products have been found to suppress PT H secretion as well. The biosynthesis of vitamin D is tightly regulated based on the serum concentrations of calcium, phosphate, PTH, and active vitamin D.
| [Source]
Vitamin D is a 9,10-secosteroid and 6 forms have been identified. The importance of vitamin D in bone (calcium homeostasis) is well established, and vitamin D has been the subject of increased attention in recent years for its role in muscle function, immunology, heart and cardiovascular disease, cancer, and insulin secretion. The vitamin D4 precursor 22,23-dihydroergosterol was present in all mushroom composites. The levels were not correlated with vitamin D4, but differed among species. Enoki mushrooms had a notably higher 22,23-dihydroergosterol content, with an average of 16.5 mg/100g compared to 4.49–8.89 mg/ 100 g in other types of mushrooms. | [storage]
Store at -20°C |
| Questions And Answer | Back Directory | [Synthesis in Skin]
Once vitamin D, enters the circulation, it is transported to the liver where it is hydroxylated to 25-hydroxyvitamin D3 (25-(OH)D3). 25-Hydroxyvitamin D3 is the major circulating form of vitamin D3 and its determination is often used to measure the vitamin D status of a patient. Although 1 ,25-(OH)2D3 has a marked effect on inhibiting proliferation of cultured human fibroblasts and keratinocytes and inducing terminal differentiation of cultured keratinocytes, there is no evidence that a deficiency in this hormone will increase proliferative activity in human skin. Thus, it would appear that 1,25-(OH)D3 is not a major regulator of dermal and epidermal proliferation and differentiation. Despite the fact that 1,25-(OH)2D3 is not a major participant in the regulation of epidermal differentiation, the observations that 1,25-(OH)D3 can inhibit the hyperproliferative activity of epidermal cells in patients with psoriasis is intriguing. It should be noted that patients with psoriasis have a normal metabolism of vitamin D to 25-hydroxyvitamin D and 1 ,25-(OH)2D3.24 Therefore, 1 ,25-(OH)2D3 and its analogs hold promise as unique pharmacologic agents for treating hyperproliFerative disorders of the skin such as psoriasis. |
|
|